Zevra Therapeutics, Inc. (ZVRA): Total Assets
$284.73M
As of 2025-12-31
$302.71M
As of 2026-06-30
+35.2%
3-year compound annual growth
+91.0%
5-year compound annual growth
+18.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $284.73M | +59.8% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $178.13M | +3.4% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $172.33M | +49.4% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $115.34M | -13.2% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $132.94M | n/m | 2023-03-07, Balance as of period end |
| 2020-12-31 | $11.21M | +6.7% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $10.51M | -60.7% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $26.75M | -49.0% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $52.46M | -38.2% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $84.89M | +55.5% | 2018-03-30, Balance as of period end |
| 2015-12-31 | $54.59M | n/c | 2017-03-10, Balance as of period end |
| 2014-12-31 | $13.71M | n/a | 2016-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $346.53M | -25.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $219.47M | -10.2% |
| Xencor Inc (XNCR) | 2025-12-31 | $875.50M | -8.0% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $1.42B | +1.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $239.34M | -5.8% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
Compare ZVRA, ZYME, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗